LAURUS LABS
Quarterly Results Analysis [Dec2023]
LAURUS LABS Quarterly Results
Consolidated | Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 Audited |
Dec2022 UnAudited |
Sep2022 UnAudited |
Jun2022 UnAudited |
Mar2022 Audited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹1,195 Cr | ₹1,224 Cr | ₹1,182 Cr | ₹1,381 Cr | ₹1,545 Cr | ₹1,576 Cr | ₹1,539 Cr | ₹1,425 Cr |
Expenses | ₹1,014 Cr | ₹1,037 Cr | ₹1,015 Cr | ₹1,095 Cr | ₹1,141 Cr | ₹1,127 Cr | ₹1,085 Cr | ₹1,028 Cr |
Operating Income | ₹181 Cr | ₹188 Cr | ₹167 Cr | ₹286 Cr | ₹404 Cr | ₹449 Cr | ₹454 Cr | ₹397 Cr |
Other Income | ₹2 Cr | ₹2 Cr | ₹4 Cr | ₹2 Cr | ₹1 Cr | ₹1 Cr | ₹2 Cr | ₹1 Cr |
Interest | ₹51 Cr | ₹42 Cr | ₹39 Cr | ₹53 Cr | ₹43 Cr | ₹40 Cr | ₹29 Cr | ₹31 Cr |
Depreciation | ₹98 Cr | ₹93 Cr | ₹91 Cr | ₹87 Cr | ₹84 Cr | ₹82 Cr | ₹71 Cr | ₹66 Cr |
Profit Before Tax | ₹35 Cr | ₹54 Cr | ₹41 Cr | ₹147 Cr | ₹278 Cr | ₹328 Cr | ₹356 Cr | ₹302 Cr |
Profit After Tax | ₹25 Cr | ₹39 Cr | ₹28 Cr | ₹107 Cr | ₹203 Cr | ₹234 Cr | ₹253 Cr | ₹232 Cr |
EPS | ₹0.43 | ₹0.69 | ₹0.46 | ₹1.91 | ₹3.77 | ₹4.33 | ₹4.68 | ₹4.29 |
Industry Peers & Returns | 1W | 1M | 1Y |
LAURUS LABS | 2.5% | -0.4% | 30.5% |
SUN PHARMACEUTICAL INDUSTRIES | 3% | 2.3% | 68.2% |
CIPLA | 2.5% | 0.4% | 71.7% |
DR REDDYS LABORATORIES | -0.2% | -4.9% | 40.3% |
ZYDUS LIFESCIENCES | 5% | 10.4% | 109.1% |
DIVIS LABORATORIES | -1.6% | -7% | 23.8% |
MANKIND PHARMA | NA | NA | NA |
TORRENT PHARMACEUTICALS | 2.9% | -2.2% | 69% |
LUPIN | 2.8% | 0% | 147.8% |
LAURUS LABS Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | -2.41 % |
Y-o-Y | -22.65 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Dec2023 | ₹1,195 Cr | -2.41 | |
Sep2023 | ₹1,224 Cr | 3.61 | |
Jun2023 | ₹1,182 Cr | -14.42 | |
Mar2023 | ₹1,381 Cr | -10.61 | |
Dec2022 | ₹1,545 Cr | -1.97 | |
Sep2022 | ₹1,576 Cr | 2.40 | |
Jun2022 | ₹1,539 Cr | 8.01 | |
Mar2022 | ₹1,425 Cr | - |
LAURUS LABS Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | -3.43 % |
Y-o-Y | -55.05 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Dec2023 | ₹181 Cr | -3.43 | |
Sep2023 | ₹188 Cr | 12.69 | |
Jun2023 | ₹167 Cr | -41.61 | |
Mar2023 | ₹286 Cr | -29.25 | |
Dec2022 | ₹404 Cr | -10.10 | |
Sep2022 | ₹449 Cr | -1.16 | |
Jun2022 | ₹454 Cr | 14.48 | |
Mar2022 | ₹397 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | -1.04 % |
Y-o-Y | -41.88 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Dec2023 | 15.18% | -1.04 | |
Sep2023 | 15.34% | 8.72 | |
Jun2023 | 14.11% | -31.77 | |
Mar2023 | 20.68% | -20.83 | |
Dec2022 | 26.12% | -8.32 | |
Sep2022 | 28.49% | -3.46 | |
Jun2022 | 29.51% | 6.00 | |
Mar2022 | 27.84% | - |
LAURUS LABS Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | -35.99 % |
Y-o-Y | -87.60 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Dec2023 | ₹25 Cr | -35.99 | |
Sep2023 | ₹39 Cr | 38.45 | |
Jun2023 | ₹28 Cr | -73.52 | |
Mar2023 | ₹107 Cr | -47.19 | |
Dec2022 | ₹203 Cr | -13.15 | |
Sep2022 | ₹234 Cr | -7.42 | |
Jun2022 | ₹253 Cr | 8.90 | |
Mar2022 | ₹232 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | -34.27 % |
Y-o-Y | -83.94 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Dec2023 | 2.11 % | -34.27 | |
Sep2023 | 3.21 % | 33.75 | |
Jun2023 | 2.4 % | -69.11 | |
Mar2023 | 7.77 % | -40.87 | |
Dec2022 | 13.14 % | -11.46 | |
Sep2022 | 14.84 % | -9.57 | |
Jun2022 | 16.41 % | 0.80 | |
Mar2022 | 16.28 % | - |
LAURUS LABS Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | -37.68 % |
Y-o-Y | -88.59 % |
Quarters | EPS | % Change | |
---|---|---|---|
Dec2023 | ₹0.43 | -37.68 | |
Sep2023 | ₹0.69 | 50.00 | |
Jun2023 | ₹0.46 | -75.92 | |
Mar2023 | ₹1.91 | -49.34 | |
Dec2022 | ₹3.77 | -12.93 | |
Sep2022 | ₹4.33 | -7.48 | |
Jun2022 | ₹4.68 | 9.09 | |
Mar2022 | ₹4.29 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD